Neuroinflammation – An Early Event in Both the History and Pathogenesis of Alzheimer’s Disease

  title={Neuroinflammation – An Early Event in Both the History and Pathogenesis of Alzheimer’s Disease},
  author={P. Eikelenboom and Erik van Exel and Jeroen J M Hoozemans and Robert Veerhuis and Annemieke J. M. Rozemuller and Willem A van Gool},
  journal={Neurodegenerative Diseases},
  pages={38 - 41}
Background: About hundred years ago, Oskar Fischer proposed that the senile plaques are the consequence of the deposition of a foreign substance that could induce an inflammatory response leading to an abnormal neuritic response of the surrounding neurons. Objectives: To show that the interest in inflammation in Alzheimer’s disease (AD) is not only an early event in the history of AD but that inflammation is also an early event in the pathogenesis of AD. Methods: Evaluation of the… 

Figures from this paper

Neuroinflammation in early and late onset Alzheimer´s disease: a multimodal analysis
This study sought to characterize the distribution of microglial cell activation in 2 neurodegenerative dementias with distinct protein signatures, Alzheimer disease and frontotemporal lobar degeneration of the TDP subtype, and to determine if there was an anatomical correlation with the phenotypes most commonly associated with these conditions.
Does the Interplay Between Aging and Neuroinflammation Modulate Alzheimer's Disease Clinical Phenotypes? A Clinico-Pathological Perspective.
The study of the delicate balance between pro-inflammatory or anti-inflammatory sides of immune players in the different ages of onset of AD would be important to understand treatment efficacy in clinical trials and eventually, not only direct treatment to early disease stages, but also the possibility of establishing different treatment approaches depending on the age of the patient.
Interleukin-18, from neuroinflammation to Alzheimer's disease.
The presented data indicate that a more complete knowledge of the molecular mechanisms underlying IL-18 implication in neuroinflammatory and neurodegenerative pathways could contribute toward the development of new therapeutic strategies for AD.
Resolution of inflammation as a therapeutic target for Alzheimer's disease
These studies show that resolution of inflammation is impaired in AD, and support the idea that stimulating the resolution ofinflammation is a potential therapeutic strategy in AD.
Early and Late CNS Inflammation in Alzheimer's Disease: Two Extremes of a Continuum?
  • A. Cuello
  • Biology, Psychology
    Trends in pharmacological sciences
  • 2017
Rodent models of neuroinflammation for
Among these models, streptozotocin, PolyI:C-induced, and p25 neuroinflammation models are compatible with the inflammation hypothesis of Alzheimer's disease.
An Integrative Overview of Non-Amyloid and Non-Tau Pathologies in Alzheimer’s Disease
A brief overview of why apolipoprotein E, lipid metabolism, neuroinflammation, and mitochondrial research have become increasingly ascendant in the AD research field is provided, and the case for studying these phenomena from an integrated perspective is presented.
Rodent models of neuroinflammation for Alzheimer’s disease
Among these models, streptozotocin, PolyI:C-induced, and p25 neuroinflammation models are compatible with the inflammation hypothesis of Alzheimer’s disease.
Inflammatory pathology markers (activated microglia and reactive astrocytes) in early and late onset Alzheimer disease: a post mortem study
The pattern of microglial cell activation and astrogliosis in brain post mortem tissue of pathologically confirmed cases of early and late onset AD (EOAD and LOAD) is characterized and their relation to age is determined.
Reviews: Serum Anticholinergic Activity: A Biomarker for Rapid Progression of Alzheimer’s Disease
The reasons why AA endogenously appeared in Alzheimer’s disease and that the serum anticholinergic activity (SAA) was suitable as one of the biological marker of AD were reviewed and cholinesterase inhibitors in mild stage and NMDA receptor antagonist in moderate stage in AD should be prescribed to prevent appearance of AA.


The significance of neuroinflammation in understanding Alzheimer’s disease
The role of inflammation in the early stage of AD pathology and particularly the role ofinflammatory in Aβ metabolism and deposition is reviewed and the possibilities of inflammation-based therapeutic strategies in AD are discussed.
Neuroinflammatory perspectives on the two faces of Alzheimer’s disease
The evidence that inflammation related events could be a critical etiological factor in certain forms of the sporadic AD is reviewed, suggesting that inflammatory mechanisms are most likely involved in the early steps of the pathological cascade.
Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology
Astroglial Activation of Extracellular-Regulated Kinase in Early Stages of Alzheimer Disease
Analysis of patterns of total and phosphorylated ERK expression in the midfrontal cortex of patients clinically and neuropathologically characterized with early, intermediate, or advanced AD suggested that astroglial ERK activation may be an important early response to the onset of AD pathology.
Inflammaging as a prodrome to Alzheimer's disease
This review fully characterize the aging immune system and explains how three novel treatments, human umbilical cord blood cells, flavanoids, and Aβ vaccination oppose the forces of inflammaging and AD-like pathology in various mouse models.
Vascular factors and markers of inflammation in offspring with a parental history of late-onset Alzheimer disease.
Hypertension and the expression of an innate pro-inflammatory cytokine profile in middle age are early risk factors of AD in old age, and provides clues for screening and preventive strategies, of which blood pressure control can be implemented directly.
Early inflammation and dementia: A 25‐year follow‐up of the Honolulu‐Asia aging study
The view that inflammatory markers may reflect not only peripheral disease, but also cerebral disease mechanisms related to dementia, and that these processes are measurable long before clinical symptoms appear, is supported.
The LPS receptor (CD14) links innate immunity with Alzheimer's disease
The data suggest that CD14 may significantly contribute to the overall neuroinflammatory response to amyloid peptide, highlighting the possibility that the enormous progress currently being made in the field of innate immunity could be extended to research on Alzheimer's disease.